Program at a Glance

Venue Breakout Session(301)
Registration 11:00-16:00
13:20-15:00
(100 mins)

Postgraduate Course 1
×

Postgraduate Course 1

June 23, 2022（Thursday）13:20-15:00 (GMT+8)
Moderator：Ming-Chih Ho (Taipei)
Moderator：Yoh Zen (London)
Conference Room：301

Time Topic Speaker
13:20-13:40 Prevention of HCC (Primary, Secondary, Tertiary) Tung-Hung Su (Taipei)
13:40-14:00 Pathology Diagnosis of HCC Yoh Zen (London)
14:00-14:20 State of the Art of CT and MRI for HCC Bang-Bin Chen (Taipei)
14:20-14:40 Surgery For Liver Cancer Ming-Chih Ho (Taipei)
14:40-15:00 Radiofrequency and Microwave Ablation of Liver Cancers Kai-Wen Huang (Taipei)
15:00-15:20
(20 mins)		 Coffee Break
15:20-17:00
(100 mins)

Postgraduate Course 2
×

Postgraduate Course 2

June 23, 2022（Thursday）15:20-17:00 (GMT+8)
Moderator：Po-Chin Liang (Taipei)
Moderator：Han Chong Toh (Singapore)
Conference Room：301

Time Topic Speaker
15:20-15:40 Liver Transplantation for HCC: Criteria & Outcomes Cheng-Maw Ho (Taipei)
15:40-16:00 TACE and TARE for HCC Yi-Sheng Liu(Tainan)
16:00-16:20 Radiotherapy for HCC Bing-Shen Huang (Taoyuan)
16:20-16:40 Systemic Therapy of HCC Han Chong Toh (Singapore)
16:40-17:00 Systemic Therapy of Cholangiocarcinoma Nai-Jung Chiang (Taipei)
18:30-21:00
(150 mins)		 Faculty Night
(by Invitation Only)
Venue Plenary Session(201) Breakout Session(301) Breakout Session(401) Breakout Session(402)
Registration 07:00-16:00
Poster & Exhibition 09:00-17:00
08:00-09:40
(100 mins)

HBV-HCC: basic and clinical 1
×

HBV-HCC: basic and clinical 1

June 24, 2022（Friday）08:00-09:40 (GMT+8)
Moderator：Jia-Horng Kao (Taipei)
Moderator：Young-Suk Lim (Seoul)
Conference Room：301

Time Topic Speaker
08:00-08:25 Natural History and Carcinogenesis of HBV Infection Rong-Nan Chien (Taoyuan)
08:25-08:50 Biomarkers Predictive of HBV-HCC Tai-Chung Tseng (Taipei)
08:50-09:15 Risk Prediction Models of HBV-HCC Hwai-I Yang(Taipei)
09:15-09:40 Prevention of Hepatitis B Virus-Related Hepatocellular Carcinoma Young-Suk Lim (Seoul)

HCV-HCC: basic and clinical 2
×

HCV-HCC: basic and clinical 2

June 24, 2022（Friday）08:00-09:40 (GMT+8)
Moderator：Ming-Lung Yu (Kaohsiung)
Moderator：Yasuhito Tanaka (Kumamato)
Conference Room：401

Time Topic Speaker
08:00-08:25 Risk Stratification of HCV-HCC before and after HCV Cure Chen-Hua Liu (Taipei)
08:25-08:50 Genetic Factors Associated with HCC Development after HCV Eradication Yasuhito Tanaka (Kumamoto)
08:50-09:15 Molecular Mechanisms Driving HCC of HCV-HCC after HCV cure Thomas F. Baumert (Strasbourg)
09:15-09:40 Prognosis of HCV-related HCC Ming-Lung Yu (Kaohsiung)
09:40-10:00
(20 mins)		 Coffee Break
10:00-11:40
(100 mins)

MAFLD/NASH-HCC: basic and clinical 3-1
×

MAFLD/NASH-HCC: basic and clinical 3-1

June 24, 2022（Friday）10:00-11:40 (GMT+8)
Moderator：Han-Chieh Lin (Taipei)
Moderator：Bin Gao (Washington, D.C.)
Conference Room：301

Time Topic Speaker
10:00-10:25 Pathogenesis of NASH and Liver Fibrosis Kuei-Chuan Lee (Taipei)
10:25-10:50 Acetaldehyde Dehydrogenase 2 Deficiency, Alcoholic Liver Disease and Cancer Bin Gao (Washington, D.C.)
10:50-11:15 MAFLD and NAFLD Diagnostic Criteria and Prevalence of Fibrosis in Asia and Western Patients. Jacob George (Sydney)
11:15-11:40 Biomarkers for NAFLD/NASH and Its Treatment Response Vincent Wong (Hong Kong)

HCC Basic science, Genomic and molecular pathogenesis 4-1
×

HCC basic science, genomic and molecular pathogenesis 4-1

June 24, 2022（Friday）10:00-11:40 (GMT+8)
Moderator：Shiou-Hwei Yeh (Taipei)
Moderator：Hidewaki Nakagawa (Yokohama)
Conference Room：401

Time Topic Speaker
10:00-10:25 Cell-matrix Interaction in The Invasion and Metastasis of Liver Cancer Sen-Yung Hsieh (Taoyuan)
10:25-10:50 Proteo-genomic Characterization of Virus-associated Liver Cancers Identifies Novel Subtypes and Therapeutic Strategies Hidewaki Nakagawa (Yokohama)
10:50-11:15 Novel Precision Mouse Models of Hepatocellular Carcinoma Amaia Lujambio (New York)
11:15-11:40 Immunogenomic Classification of Primary Liver Cancer Daniela Sia (New York)

Oral Presentation
×

Oral Presentation

June 24, 2022（Friday）10:00-11:40 (GMT+8)
Moderator：Sheng-Nan Lu (Kaohsiung)
Moderator：Cheng-Yuan Peng (Taichung)
Conference Room：402

Presenting No. Presentation Time Paper Number Presenter Topic
1 10:00-10:15 129 Ming-Lung Yu (Kaohsiung) Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
2 10:15-10:30 187 Wen-Juei Jeng (Taoyuan) Serum Soluble Program Cell Death-1 is Predictive of Hepatocellular Carcinoma in Untreated Chronic Hepatitis B Patients
3 10:30-10:45 231 Chiao-Ling Li (Taipei) New Classification of HBV-related HCC by Distinct Genetic Mutations
4 10:45-11:00 195 Tai-Chung Tseng (Taipei) Hepatitis B Core-related Antigen Stratifies The Risk of Liver Cancer in HBeAg-negative Patients with Indeterminate Phase
5 11:00-11:15 186 Wen-Juei Jeng (Taoyuan) Serum Soluble Programmed Death-1 Levels Predict The Spontaneous HBeAg Seroclearance in Chronic Hepatitis B
11:40-13:00
(80 mins)

Luncheon Symposium by Medtronic
×

Luncheon Symposium by Medtronic

June 24, 2022（Firday）11:40-13:00 (GMT+8)
Conference Room：401

Time Topic Speaker
11:40-12:00 Opening
12:00-12:30 Lodized-oil CT Guided Ablation in Metastatic Liver Tumors Chih-Horng Wu (Taipei)
12:30-13:00 Microwave Ablation Solution for Liver Cancer Chen-Chun Lin (Taipei)
13:00-14:40
(100 mins)

MAFLD/NASH-HCC: basic and clinical 3-2
×

MAFLD/NASH-HCC: basic and clinical 3-2

June 24, 2022（Friday）13:00-14:40 (GMT+8)
Moderator：Chia-Yen Dai (Kaohsiung)
Moderator：Daniel Q. Huang (Singapore)
Conference Room：301

Time Topic Speaker
13:00-13:30 Global Epidemiology of NAFLD-related HCC: Trends, Risk Factors, and Surveillance Daniel Q. Huang (Singapore)
13:30-14:00 Risks and Clinical Predictors of Cirrhosis and Hepatocellular Carcinoma Diagnoses in Adults with Diagnosed NAFLD: Real-world Study of 18 Million Patients in Four European Cohorts William Alazawi (London)
14:00-14:30 Diabetes and The Risk of Hepatocellular Carcinoma in Cirrhosis Patients with NAFLD Ju Dong Yang (Los Angeles)
14:30-14:40 Panel Discussion

HCC basic science, immunopathogenesis and microenvironment 4-2
×

HCC BASIC SCIENCE, IMMUNOPATHOGENESIS AND MICROENVIRONMENT 4-2

June 24, 2022（Friday）13:00-14:40 (GMT+8)
Moderator：Chun-Yen Lin (Taoyuan)
Moderator：JunHao Hu (Shanghai)
Conference Room：401

Time Topic Speaker
13:00-13:25 Immune Regulation in Tumor Immunotherapy: The Role of PMN-MDSCs Chun-Yen Lin (Taoyuan)
13:25-13:50 Hepatic Stellate Cell Activation Roadmap in Liver Fibrosis and Its Application JunHao Hu (Shanghai)
13:50-14:15 The role of CD4+ T cells in HCC treatment Tim F. Greten (Montgomery)
14:15-14:40 The Role of Innate/Adaptive Immune Cells in NASH - Consequences for Liver Cancer Therapy Mathias Heikenwalder (Heidelberg)

Oral Presentation
×

Oral Presentation

June 24, 2022（Friday）13:00-14:40 (GMT+8)
Moderator：Jia-Horng Kao (Taipei)
Moderator：Shi-Ming Lin (Taoyuan)
Conference Room：402

Presenting No. Presentation Time Paper Number Presenter Topic
1 13:00-13:15 113 Te-Sheng Chang (Chiayi) Non-B, Non-C Hepatocellular Carcinoma in An HBV- and HCV-endemic Area: A Community-based Prospective Longitudinal Study
2 13:15-13:30 132 Sheng-Hung Chen (Taichung) Combined Liver Stiffness and Α-fetoprotein Further beyond The Sustained Virologic Response Visit as Predictors of Long-term Liver-related Events in Patients With Chronic Hepatitis C
3 13:30-13:45 158 Pei-Chang Lee (Taipei) Declined Biosynthetic Functions of Gut Microbiota Associate with Decreased Serum Amino Acids in Cirrhotic Patients with Sarcopenia
4 13:45-14:00 227 Kuo-Chin Chang (Kaohsiung) HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Related Liver Cirrhosis Patient Long-tern Effect of Antiviral Treatment
5 14:00-14:15 105 I-Cheng Lee (Taipei) Determinants of Survival after Sorafenib-Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
14:40-14:55
(15 mins)		 Coffee Break
14:55-15:20
(25 mins)		 Opening Ceremony(14:55-15:20)
15:20-15:50
(30 mins)		 State-of-Art Lecture
National Policy and Achievement of HCC Control in Taiwan
Moderator：Han-Chieh Lin (Taipei)
Speaker：Chien-Jen Chen (Taipei)
Conference Room：201
15:50-16:20
(30 mins)		 Chairman Lecture
Towards Elimination of HBV and Related HCC: What We Learn from Professor Ding-Shinn Chen?
Moderator：Pei-Jer Chen (Taipei)
Speaker：Chun-Jen Liu (Taipei)
Conference Room：201
16:20-16:50
(30 mins)		 Keynote Lecture(1)
Recent Progress and Future Directions of HCC Systemic Therapies: The Need for HCC-specific Targets and Regimens
Moderator：Chien-Jen Chen (Taipei)
Speaker：Pei-Jer Chen (Taipei)
Conference Room：201
16:50-18:10
(80 mins)

Evening Symposium by Gilead & Harvester
×

Evening Symposium by Gilead & Harvester

June 24, 2022（Firday）16:50-18:10 (GMT+8)
Conference Room：201

Time Topic Speaker Moderator
16:50-16:55 Opening Remarks Cheng-Yuan Peng (Taichung)
16:55-17:25 Tactics on Management in CHB Patients: The Efficacy and Safety of Tenofovir Alafenamide Chia-Yen Dai
(Kaohsiung)		 Cheng-Yuan Peng
(Taichung)
17:25-17:55 Tactics on Prevention of Chemotherapy Induced HBV Reactivation and HCC Recurrence I-Cheng Lee
(Taipei)		 Chun-Jen Liu
(Taipei)
17:55-18:10 Panel Discussion and Closing Remarks ALL Faculties
Chun-Jen Liu (Taipei)

Evening Symposium by BMS/Ono
×

Evening Symposium by BMS/Ono

June 24, 2022（Firday）16:50-18:10 (GMT+8)
Conference Room：301

Time Topic Speaker Moderator
16:50-16:55 Opening Yi-Hsiang Huang (Taipei)
16:55-17:25 HBV Flares under Current Reimbursement Criteria-Define and Take Action for High-risk Population Yi-Hsiang Huang (Taipei) Jia-Horng Kao (Taipei)
17:25-17:55 Challenges of Combination Therapy with Immune Checkpoint Inhibitors for Hepatocellular Carcinoma Yu-Yun Shao (Taipei) Yi-Hsiang Huang (Taipei)
17:55-18:10 Panel Discussion and Closing Yu-Yun Shao (Taipei)
Yi-Hsiang Huang (Taipei)
Jia-Horng Kao (Taipei)

Evening Symposium by MSD
×

Evening Symposium by MSD

June 24, 2022（Firday）16:50-18:10 (GMT+8)
Conference Room：401

Time Topic Speaker Moderator
16:50-17:05 HCC Treatment Up to Date - Guidance and Consensus Overview Tung-Hung Su (Taipei)
17:05-17:30 Panelists Discussion Tung-Hung Su (Taipei) Han-Chieh Lin (Taipei)
Shi-Ming Lin (Taoyuan)
Kai-Wen Huang (Taipei)
Chia-Hsun Hsieh (Taoyuan)
17:30-17:45 Optimize Immunotherapy and TKI AE Management - Overview Chia-Hsun Hsieh (Taoyuan)
17:45-18:10 Panelists Discussion Chia-Hsun Hsieh (Taoyuan) Han-Chieh Lin (Taipei)
Shi-Ming Lin (Taoyuan)
Kai-Wen Huang (Taipei)
Tung-Hung Su (Taipei)
18:30-21:30
(180 mins)		 Gala Dinner (Cancelled)
Venue Plenary Session(201) Breakout Session(301) Breakout Session(401) Breakout Session(402)
Registration 07:00-14:30
Poster & Exhibition 09:00-15:30
08:00-09:30
(90 mins)

HCC diagnosis 5
×

HCC diagnosis 5

June 25, 2022（Saturday）08:00-09:30 (GMT+8)
Moderator：Shiu-Feng Huang (Miaoli)
Moderator：Young Nyun Park (Seoul)
Conference Room：301

Time Topic Speaker
08:00-08:20 Pathology Diagnosis of Hepatocellular Carcinoma Young Nyun Park (Seoul)
08:20-08:40 Immune Checkpoint Inhibitor-Related Liver Injury in HCC and Non-HCC Patients Yoh Zen (London)
08:40-09:00 Contrast-enhanced Ultrasound (CEUS) of Liver Tumors Using Sonazoid: Pros and Cons Yi-Hong Chou (Taipei)
09:00-09:20 State-of-the-art MRI for HCC Yu-Ting Kuo (Tainan)
09:20-09:30 Panel Discussion

Epidemiology and prevention of HCC 11
×

Epidemiology and prevention of HCC 11

June 25, 2022（Saturday）08:00-09:30 (GMT+8)
Moderator：Sheng-Nan Lu (Kaohsiung)
Moderator：Yasuhiro Asahina (Tokyo)
Conference Room：401

Time Topic Speaker
08:00-08:20 Global Trends, Determinants, and Prevention of Hepatocellular Carcinoma Hye-Won Lee (Seoul)
08:20-08:40 Genetic Predisposition to Hepatocellular Carcinoma Mei-Hsuan Lee (Taipei)
08:40-09:00 Biomarkers for The Screening and Early Detection of Hepatocellular Carcinoma Yasuhiro Asahina (Tokyo)
09:00-09:20 The National HCC Multidisciplinary Team Improves Clinical Care Quality Sheng-Nan Lu (Kaohsiung)
09:20-09:30 Panel Discussion

Oral Presentation-Young Investigator Award
×

Oral Presentation-Young Investigator Award

June 25, 2022（Saturday）08:00-09:30 (GMT+8)
Moderator：Han-Chieh Lin (Taipei)
Moderator：Ming-Lung Yu (Kaohsiung)
Conference Room：402

Presenting No. Presentation Time Paper Number Presenter Topic
1 08:00-08:15 153 Yen-Chun Liu (Taoyuan) Different Viral Kinetics in Cirrhotic and Non-cirrhotic HBeAg Negative Chronic Hepatitis B Patients Lead to Different Off-therapy Relapse Probability and Severity
2 08:15-08:30 168 Shang-Chin Huang (Taipei) Concurrent Metabolic Dysfunction-Associated Fatty Liver Disease Reduces The Risk of Hepatocellular Carcinoma in Patients with Untreated Chronic Hepatitis B
3 08:30-08:45 213 Te-Wei Tseng (Taoyuan) Re-classification of Tumor Associated Neutrophils Based on The Maturation Stages is Highly Correlated with Suppression Function and Metabolic Profile in a Murine Hepatoma Model
4 08:45-09:00 222 Chi-Jung Wu (Taipei) Efficacy of Systemic Treatment for Unresectable Hepatocellular Carcinoma Associated with Non-viral Hepatitis Etiology
5 09:00-09:15 223 Chun-Ming Hong (Taipei) Combination of Post-DAA Liver Fibrosis and Neutrophil-to-Lymphocyte Ratio Predicts The Development of Liver-Associated Complications in Chronic Hepatitis C Patients Who Achieve Sustained Virologic Response
6 09:15-09:30 62 Hung-Yao Lin (Taipei) Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection
09:30-09:55
(25 mins)		 Keynote Lecture(2)
Current Issues in HCC Surveillance
Moderator：Yi-Hsiang Huang (Taipei)
Speaker：Amit G. Singal (Dallas)
Conference Room：201
09:55-10:20
(25 mins)		 Keynote Lecture(3)
Gut Microbiota and Hepatocellular Carcinoma
Moderator：Jia-Horng Kao (Taipei)
Speaker：Ming-Shiang Wu (Taipei)
Conference Room：201
10:20-10:35
(15 mins)		 Coffee Break
10:35-11:00
(25 mins)		 Keynote Lecture(4)
Unmet Needs in HCC Therapy
Moderator：Chun-Jen Liu (Taipei)
Speaker：Richard S. Finn (Santa Monica)
Conference Room：201
11:00-12:30
(90 mins)

HCC treatment – curative treatment 6
×

HCC treatment – curative treatment 6

June 25, 2022（Saturday）11:00-12:30 (GMT+8)
Moderator：Shi-Ming Lin (Taoyuan)
Moderator：Shuichiro Shiina (Tokyo)
Conference Room：301

Time Topic Speaker
11:00-11:20 Liver Resection for Nonalcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma Jai Young Cho (Seongnam)
11:20-11:40 Prognostic Impact of Concurrent Nonalcoholic Fatty Liver Disease in Patients with Chronic Hepatitis B‐related Hepatocellular Carcinoma Yoon Jun Kim (Seoul)
11:40-12:00 Radiofrequency and Microwave ablation for Hepatocellular carcinoma Shuichiro Shiina (Tokyo)
12:00-12:20 Non-Thermal Ablation for Hepatocellular Carcinoma over Risky Area. Kai-Wen Huang (Taipei)
12:20-12:30 Panel Discussion

HCC treatment – systemic therapy 8
×

HCC treatment – systemic therapy 8

June 25, 2022（Saturday）11:00-12:30 (GMT+8)
Moderator：Chiun Hsu (Taipei)
Moderator：Masatoshi Kudo (Osaka)
Conference Room：401

Time Topic Speaker
11:00-11:20 Changing Practice of Systemic Therapy for Intermediate-stage HCC in Japan Masatoshi Kudo (Japan)
11:20-11:40 Incorporating New Regimens of Systemic Therapy into Current Practice in Asia Stephen L. Chan (Hong Kong)
11:40-12:00 Role of Molecular Targeted Agents in the Era of ICI-based Combination Therapy in Advanced HCC Yi-Hsiang Huang (Taiwan)
12:00-12:20 Perspective of Systemic Therapy for Hepatocellular Carcinoma Ann-Lii Cheng (Taiwan)
12:20-12:30 Panel Discussion
12:30-13:50
(80 mins)

Luncheon Symposium by Gilead & Harvester
×

Luncheon Symposium by Gilead & Harvester

June 25, 2022（Saturday）12:30-13:50 (GMT+8)
Conference Room：201

Time Topic Speaker Moderator
12:30-12:35 Opening Han-Chieh Lin
(Taipei)
12:35-13:00 The Potential Solution for Broad Screening and Link to Care in Asia Rong-Nan Chien
(Taoyuan)		 Han-Chieh Lin
(Taipei)
13:00-13:25 The HCV Treatment before and during COVID-19 Pandemic Chen-Hua Liu
(Taipei)		 Jia-Horng Kao
(Taipei)
13:25-13:45 Panel Discussion All Speaker and Moderator
13:45-13:50 Closing Jia-Horng Kao (Taipei)

Luncheon Symposium by Roche
×

Luncheon Symposium by Roche

June 25, 2022（Saturday）12:30-13:50 (GMT+8)
Conference Room：301

Time Topic Speaker Moderator
12:30-12:35 Opening Ming-Lung Yu (Kaohsiung)
12:35-13:05 The Developing Biomarkers Enhance the Sensitivity on Early HCC Diagnosis. Chung-Feng Huang
(Kaohsiung)		 Ming-Lung Yu
(Kaohsiung)
13:05-13:10 Q&A Chung-Feng Huang (Kaohsiung)
Ming-Lung Yu (Kaohsiung)
13:10-13: 40 Maximize 1L Benefits: How Tecentriq and Avastin Re-shapes the Real-world uHCC Sequence? Masatoshi Kudo (Osaka) Yi-Hsiang Huang (Taipei)
13:40-13:45 Q&A Masatoshi Kudo (Osaka)
Yi-Hsiang Huang (Taipei)
13:45-13:50 Closing Yi-Hsiang Huang (Taipei)

Luncheon Symposium by Bayer
×

Luncheon Symposium by Bayer

June 25, 2022（Saturday）12:30-13:50 (GMT+8)
Conference Room：401

Time Topic Speaker Moderator
12:30-12:35 Opening Ann-Lii Cheng (Taipei)
12:35-13:05 Maximize aHCC OS Benefits with Sequential Systemic Therapy - VGH-TPE NexSt RWD Sharing Yi-Hsiang Huang (Taipei) Ann-Lii Cheng (Taipei)
13:05-13:10 Discussion Yi-Hsiang Huang (Taipei) Ann-Lii Cheng (Taipei)
13:10-13:40 NexSt Live Longer! Break 1L OS Barrier with the Well-proven Sequential Therapy for aHCC Patients -CMUH NexSt RWD Sharing Hung-Wei Wang (Taichung) Ann-Lii Cheng (Taipei)
13:40-13:45 Discussion Hung-Wei Wang (Taichung) Ann-Lii Cheng (Taipei)
13:45-13:50 Closing Ann-Lii Cheng (Taipei)

Luncheon Symposium by Eisai
×

Luncheon Symposium by Eisai

June 25, 2022（Saturday）12:30-13:50 (GMT+8)
Conference Room：402

Time Topic Speaker Moderator
12:30-12:40 Opening Sheng-Nan Lu (Kaohsiung)
12:40-13:10 New Paradigm of Treatment Strategy and Optimal Use of Lenvatinib in HCC Ming-Shun Wu (Taipei)
13:10-13:40 Navigating Treatment Option in Advanced HCC –From Clinical Trial to Real World Data Hung-Chih Yang (Taipei)
13:40-13:50 Discussion & Closing Sheng-Nan Lu (Kaohsiung)
13:50-15:20
(90 mins)

HCC treatment – interventional radiology 7
×

HCC treatment – interventional radiology 7

June 25, 2022（Saturday）13:50-15:20 (GMT+8)
Moderator：Rheun-Chuan Lee (Taipei)
Moderator：Toshihiro Tanaka (Kashihara)
Conference Room：301

Time Topic Speaker
13:50-14:10 Y90 versus TACE for HCC Riad Salem (Chicago)
14:10-14:30 Superselective Conventional TACE for Hepatocellular Carcinoma Shiro Miyayama (Fukui)
14:30-14:50 Role of DEB-TACE in The New Era of Systemic Therapy Toshihiro Tanaka (Kashihara)
14:50-15:10 Lipiodol-CT Guided Liver Tumor Ablation Po-Chin Liang (Taipei)
15:10-15:20 Panel Discussion

Cholangiocarcinoma 9
×

Cholangiocarcinoma 9

June 25, 2022（Saturday）13:50-15:20 (GMT+8)
Moderator：Li-Tzong Chen (Kaohsiung)
Moderator：Do-Youn Oh (Seoul)
Conference Room：401

Time Topic Speaker
13:50-14:10 Pathology Diagnosis of Cholangiocarcinoma Young Nyun Park (Seoul)
14:10-14:30 Immunotherapy in Biliary Tract Cancer Do-Youn Oh (Seoul)
14:30-14:50 Precision Medicine in Biliary Tract Cancer Ming-Huang Chen (Taipei)
14:50-15:10 Epigenetic Vulnerabilities: Therapeutic Opportunity for Intrahepatic Cholangiocarcinoma Li-Tzong Chen (Kaohsiung)
15:10-15:20 Panel Discussion
15:20-15:40
(20 mins)		 Coffee Break
15:40-17:10
(90 mins)

AI for HCC 10
×

AI for HCC 10

June 25, 2022（Saturday）15:40-17:10 (GMT+8)
Moderator：Tung-Hung Su (Taipei)
Moderator：Julien Calderaro (Créteil)
Conference Room：301

Time Topic Speaker
15:40-16:00 State-of-the-art of AI in Radiology for the Diagnosis of HCC Michael D. Kuo (Hong Kong)
16:00-16:20 AI in The Diagnosis and Management of HCC by Electric Medical Record Masaya Sato (Tokyo)
16:20-16:40 Application of AI in Pathology for The Diagnosis of HCC Julien Calderaro (Créteil)
16:40-17:00 AI in the Diagnosis and Management of HCC by Multi-Omics Integration Bin Chen (Michigan)
17:00-17:10 Panel Discussion

AP region HCC summit 12
×

AP region HCC summit 12

June 25, 2022（Saturday）15:40-17:10 (GMT+8)
Moderator：Jia-Horng Kao(Taipei)、Ann-Lii Cheng(Taipei)
Moderator：Shiv Kumar Sarin (New Delhi)
Conference Room：401

Time Topic Speaker
15:40-15:55 Screening and Management of Hepatocellular Carcinoma in Vietnam Pham Cam Phuong (Hanoi)
15:55-16:10 HCC in Philippines: Ablation experience Diana Alcantara-Payawal (Manila)
16:10-16:25 The Changing HCC Epidemiology and its Management Rosmawati Mohamed (Kuala Lumpur)
16:25-16:40 Management of Hepatocellular Carcinoma in Thailand Tawesak Tanwandee (Bangkok)
16:40-16:55 Spectrum and Management of Hepatocellular carcinoma in India Shiv Kumar Sarin (New Delhi)
16:55-17:10 Management of Hepatocellular Carcinoma in Indonesia Rino A. Gani (Jakarta)
17:20-17:40
(20 mins)		 Closing Ceremony